Home › Research › Tau biomarkers
CSF and plasma biomarkers in cerebral amyloid angiopathy: A single-center study and a systematic review/meta-analysis
Theodorou A, Tsantzali I, Stefanou MI, Sacco S, Katsanos AH, Shoamanesh A, Karapanayiotides T, Koutroulou I et al.. European stroke journal, 2024-06-13
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction There are limited data regarding cerebrospinal fluid (CSF) and plasma biomarkers among patients with Cerebral Amyloid Angiopathy (CAA). We sought to investigate the levels of four biomarkers [β-amyloids (Aβ42 and Aβ40), total tau (tau) and phosphorylated tau (p-tau)] in CAA patients compared to healthy controls (HC) and patients with Alzheimer Disease (AD). Patients and methods A systematic review and meta-analysis of published studies, including also a 5 year single-center cohort study, with available data on CSF and plasma biomarkers in symptomatic sporadic CAA versus HC and AD was conducted.
What this study adds
Evidence grade: High
This is a pooled review. This review compared CSF and plasma biomarker levels in people with cerebral amyloid angiopathy against healthy controls and people with Alzheimer's disease. It is about improving diagnosis and distinguishing these conditions, not about treating or preventing Alzheimer's.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Theodorou, A., Tsantzali, I., Stefanou, M. I., Sacco, S., Katsanos, A. H., Shoamanesh, A., et al. (2025). CSF and plasma biomarkers in cerebral amyloid angiopathy: A single-center study and a systematic review/meta-analysis. European stroke journal. https://doi.org/10.1177/23969873241260538
Vancouver
Theodorou A, Tsantzali I, Stefanou MI, Sacco S, Katsanos AH, Shoamanesh A, et al. CSF and plasma biomarkers in cerebral amyloid angiopathy: A single-center study and a systematic review/meta-analysis. European stroke journal. 2025. doi:10.1177/23969873241260538. PMID: 38869035.
BibTeX
@article{theodorou2025-38869035,
author = {Theodorou, A. and Tsantzali, I. and Stefanou, M. I. and Sacco, S. and Katsanos, A. H. and Shoamanesh, A. and Karapanayiotides, T. and Koutroulou, I. and others},
title = {{CSF and plasma biomarkers in cerebral amyloid angiopathy: A single-center study and a systematic review/meta-analysis}},
journal = {European stroke journal},
year = {2025},
doi = {10.1177/23969873241260538},
pmid = {38869035},
url = {https://doi.org/10.1177/23969873241260538}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We sought to investigate the levels of four biomarkers [β-amyloids (Aβ42 and Aβ40), total tau (tau) and phosphorylated tau (p-tau)] in CAA patients compared to healthy controls (HC) and patients with Alzheimer Disease (AD).
- Patients and methods A systematic review and meta-analysis of published studies, including also a 5 year single-center cohort study, with available data on CSF and plasma biomarkers in symptomatic sporadic CAA versus HC and AD was conducted.
- Biomarkers' comparisons were investigated using random-effects models based on the ratio of mean (RoM) biomarker concentrations.
- RoM 1 indicate lower and higher biomarker concentration in CAA compared to another population, respectively.
Why it matters
This review compared CSF and plasma biomarker levels in people with cerebral amyloid angiopathy against healthy controls and people with Alzheimer's disease. It is about improving diagnosis and distinguishing these conditions, not about treating or preventing Alzheimer's.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designsystematic review
- Evidence strengthHigh
How this study scored 60/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European stroke journal) |
| Journal's citation record | 0 / 4 | European Stroke Journal: journal h-index 60 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 3 / 7 | Cited 24 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 24 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Georgios K. Tsivgoulis: h-index 90 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 20 institution(s) in 7 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38869035) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1177/23969873241260538
- PubMed: 38869035
- Original source →
- Free full text: European Stroke Journal →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.